Symptom relief sustained to three years: Improvements in the stringent endpoints HiSCR75, HiSCR90, and HiSCR100 at one year were sustained to three years in 81.2%, 64.3%, and 50.1% of patients, respectively*
Resolution of inflammatory lesions: Of patients who achieved IHS4-100 (European clinical metric to assess the severity of HS1) at year one, 64.3% achieved and maintained this complete resolution of inflammatory lesions through to two years*
Impact of earlier treatment: Across the high-effica